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Objective: Studies report clustering of cardiovascular risk factors and increased cardiovascular events in healthy first-degree
relatives (FDR) of subjects with intermittent claudication (IC). Family history is an independent risk factor in coronary artery
disease but the role of genetic factors is undefined in peripheral arterial disease. The fibrin clot is the final product of the
atherothrombotic process and is subject to genetic influence. We proposed that healthy male FDR of subjects with IC possess
abnormalities in their fibrin clots.
Methods:This was a case-control family study. The FDR were recruited from claudicants attending vascular surgery out-patient
clinics with the control subjects being recruited from the local primary care register. A total of 106 white European male FDR
of male subjects with IC were age matched with 107 white European male control subjects from an identical geographic area.
The control subjects had no FDR with a history of symptomatic cardiovascular disease, and subjects from both groups were
free from a personal history of symptomatic cardiovascular disease or diabetes mellitus. Ex vivo assays for fibrin clot
permeation, fiber thickness, factor XIII cross-linking activity, and fibrinolysis were performed on the plasma of the above
subjects. In addition, linear regression analysis was undertaken to determine factors associated with clot parameters.
Results: For controls and FDR, respectively, fiber thickness by turbidity was 0.75 (0.67-0.93) vs 0.86 (0.75-0.98) (P< .001), and
FXIII cross-linking activity was 105% (87-141) vs 133% (103-155) (P< .001). On confocal microscopy, fibers measured 315.8
(307.0-324.6) vs 405.1 (397.6-412.6) nm (P < .001), and lysis front velocity was 12.66 (6.38-18.94) vs 4.83 (2.50-7.17),
m/min (P  .018). Linear regression analysis revealed cholesterol was associated with changes in certain clot parameters.
Conclusion: The healthy FDR of subjects with IC produce clots which have thicker fibers, increased cross-linking, and
resistance to fibrinolysis when compared to controls. This supports the potential genetic basis of peripheral arterial
disease and highlights that cholesterol may contribute to this abnormal structure. This suggests that the FDR of subjects
with IC, an apparently healthy sub-group of the population, have an elevated cardiovascular risk associated with
abnormalities in their clot structure. ( J Vasc Surg 2008;48:1497-503.)
Clinical Relevance: This study furthers our understanding of the pathophysiology of peripheral arterial disease, and is
supported by our previous work on abnormalities in fibrin clot structure in the formation and progression of coronary
artery disease. The study highlights the possible contribution of familial factors through transmission of an abnormal clot
structure to the development of symptomatic cardiovascular disease. Most importantly, this work identifies the
apparently healthy FDR group of the population as potentially at high cardiovascular risk and raises the question
regarding the need for primary prevention in this group.From the Division of Cardiovascular and Diabetes Researcha and Biostatis-
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Vascular Surgery.doi:10.1016/j.jvs.2008.07.010The fibrin clot is the final product of the atherothrombotic
process and the structure of this clot is subject to genetic
influence with twin studies revealing heritability estimates
of 39-46% for the phenotype of the final fibrin clot.1,2
Furthermore, it has been demonstrated that the healthy
first degree relatives (FDR) of subjects with premature
coronary artery disease (CAD) form abnormal fibrin clots.3
A positive family history is established as an independent
risk factor for CAD4 and heritability studies support the
causal involvement of genetic factors in cardiovascular dis-
ease (CVD),5,6 but the role of genetic factors in peripheral
arterial disease (PAD) has not been defined.
PAD affects 27 million subjects through North Amer-
ica and Europe7 with subjects suffering from intermittent
claudication (IC) having up to a sixfold increase in risk of
cardiovascular mortality when compared to a normal pop-
ulation.8 Studies have shown increased atherothrombotic
events in the healthy FDR of subjects with PAD9 and
clustering of atherothrombotic risk factors and insulin re-
sistance,10 which may indicate an increased familial risk.
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hypothesis that the healthy male FDR of male subjects with
IC possess abnormalities in their fibrin clot structure that
could lead to an increased cardiovascular risk. We also
assessed the relationships between clinical, biochemical,
and hemostatic factors, genetic polymorphisms, and the
biophysical properties of these fibrin clots.
METHODS
Ethical consideration. The study was granted ethical
approval by the Leeds (West) Teaching Hospitals NHS
Trust Local Research Ethics Committee (04/008).
Sample size calculation. A previous study from our
institute involving 100 healthy FDR of subjects with CAD
and 100 control subjects, showed significant differences in a
number of clot parameters.3 With regard to the measurement
of clot permeability parameterKs (vide infra) and its variability,
based on the data from a pilot study in 49 healthy subjects, a
sample size of 106 FDR, and 107 controls enrolled in this
study is large enough to detect a difference of 0.9 10-9 cm2
at the 5% significance level with 80% power.
Subjects. We previously recruited 108men with inter-
mittent claudication (probands), 165 of their healthy male
FDR, and 165 male control subjects.10 As there are known
gender differences in hemostatic parameters, andPAD ismore
common in men, solely male subjects were recruited to main-
tain the power of the study. Although these subjects have
previously been studied for certain atherothrombotic risk fac-
tors,10 this work with fibrin clot structure is entirely original.
Due to plasma availability, 106 white European male
FDR were available for this study and, using a pooled
matching system, were matched for age with 107 white
Europeanmale controls. This FDR group was composed of
78 sons (73.6%) and 28 brothers (26.4%).
The healthy FDR were between 18 and 65 years of age
with no personal history of clinical CVD or diabetes melli-
tus (DM). These subjects were recruited from probands
identified from consecutive patients attending the vascular
out-patient department. The probands all had intermittent
claudication as defined by the Edinburgh Claudication
Questionnaire,11 with stable symptoms for more than 6
months, an Ankle Brachial Pressure Index (ABPI) of less
than 0.9, and PAD confirmed on angiography or duplex
scanning. None of the subjects had critical limb ischemia
and their clinical characteristics were as follows: median age
62 years (interquartile range [IQR] 57-65 years), with a
median age at diagnosis of 54 years (50-60) and a median
walking distance of 200meters (IQR 100-250m); 48% had
undergone intervention for their PAD, with 18.5% under-
going angioplasty or stenting, 25% having an endarterec-
tomy or bypass, and 4.5% having both endovascular and
surgical intervention; 22% suffered from coexistent DM and
46% had coexistent CVD, in terms of ischemic heart disease
and/or cerebrovascular events.10 The control subjects had no
personal or family history of clinical CVD or DM.
Clinical assessment, blood sampling, data collec-
tion, hemostatic factor measurement, and genotyping.
The control subjects and FDR were assessed for IC andangina using the Edinburgh Claudication11 and Rose An-
gina12 questionnaires. To further define the groups, a
detailed history was taken with specific regard to personal
and family clinical CVD, along with drug history and
physical assessment, including electrocardiogram (ECG)
and ABPI.10 Subjects were excluded from the study if
questionnaires were positive for CVD, they had a personal
or family CVDhistory incompatible with their study group,
were taking anti-platelet, anti-hypertensive, hypoglycemic,
or lipid-lowering agents, or had an abnormal ABPI or
ECG. These ensured subjects with asymptomatic CVD
were not included, and were not taking any medications
that are known to influence clot structure.13-16 The meth-
ods used to sample, prepare, and store the fresh citrated
plasma samples, along with the assays for the hemostatic
factors (HOMA,17 Fibrinogen, D-dimer, tPA, PAI-1, FVII
activity, vWF, FXIII complex, and FXIII B-subunit), and
polymorphisms in PA1-1 4G/5G, FXIII Val34Leu, FVII
R353Q, fibrinogen AThr312Ala, fibrinogen BG455A
were described previously.10
We appreciate control subjects may not be fully aware
of the detailed history of their FDR and, to minimize any
inaccuracy, the detailed interview was performed by a phy-
sician. In addition, we believe, due to the current attitudes
towards health awareness, controls would have a good
knowledge of their relatives’ health history. Finally, if the
FDR of some control subjects did have symptomatic CVD,
this would actually have a negative effect on the study.
Fibrin clot permeation analysis. Plasma samples were
incubated with 1 U/mL human -thrombin (American Di-
agnostica, Stamford, Conn) and 20mMCaCl2 (Fisher Scien-
tific UK, Leicestershire, United Kingdom) in open tubes and
placed in a room temperature humidity chamber for 2 hours.
The tubes containing the sample clots were connected to a
reservoir of 0.05 M TRIS, 0.1 M NaCl at pH 7.4 (Fisher
Scientific) with a 4 cm pressure drop using plastic tubing.
After the clot had been washed for 1 hour, the flow rate of
buffer through the fibrin clot was measured by the exact
timing and weighing of six sequential drops of buffer that
passed through the clot while maintaining a constant pressure
gradient. From this permeation data, the Darcy constant or
Ks, which represents the average pore size within the clot, can
be calculated as previously described.18 The samples were
performed in duplicate and the mean of the duplicates was
taken to represent the Ks for that sample.
Fibrin polymerization by turbidity analysis. Plasma
was diluted with an equal volume of 0.05 M TRIS, 0.1 M
NaCl at pH 7.4 (Fisher Scientific) in a microtiter plate. Clot
formation was triggered by the addition of 0.5 U/mL -1
human thrombin (American Diagnostica) and 16 mM
CaCl2(Fisher Scientific) creating a 1/3 dilution of the
sample. Immediately on addition of the thrombin and
calcium, the turbidity analysis was commenced. Using Reve-
lation software (Revelation, London, United Kingdom) a
Dynex MRX TC II (Dynex Technologies, West Sussex,
UnitedKingdom)plate readermeasured sequential absorben-
cies (optical densities) every 10 seconds at 350 nm for 20
minutes. These samples were performed in duplicate, and the
s (23
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baseline absorbency from that at 20minutes when the turbid-
ity curve had reached a plateau. The mean of the duplicates
were taken as the MA for that sample. This assay is based on
the MA reflecting the number of protofibrils per fiber, and,
therefore, average clot fiber thickness.19
Factor XIII cross-linking activity. A FXIII biotinyl-
ated pentylamine incorporation assay is highly specific inmea-
suring cross-linking activity in plasma.20 The FXIII activity
levels were determined as described previously, and expressed
as a percentage of normal pooled plasma.20 The mean of the
duplicates were taken to be representative of that sample.
Laser scanning confocal microscopy. Laser scanning
confocal microscopy (LSCM) allows direct quantification
of fiber thickness with real time assessment of the rate of
fibrinolysis using the following methodology, and due to
financial constraints this was performed on 15 samples from
each group. Samples were chosen to represent average
fibrin structure characteristics of each particular study
group. To this extent, fiber thickness as determined by
turbidity were ranked for each group, and samples for
LSCM analysis were selected from each group based on
average fiber thickness (ie, the sample with the mean fiber
thickness for a particular study group was selected with the
seven samples immediately higher and lower than the mean
sample). This selection process was employed to ensure the
samples were representative of that group.
The plasma was mixed with 1 U/mL -1 human
thrombin (Sigma-Aldrich, St. Louis, Mo) and 15 mM
CaCl2and incubated in a micro-chamber for 30 minutes in
a moist atmosphere at room temperature. Fibrin clots were
washed with 0.05 M TRIS, 0.1 M NaCl at pH 7.4. Once
the buffer had permeated through, the clots were labeled
with a solution of 5 nm colloidal gold beads (Sigma-
Aldrich) at a concentration of 2.5  1012 mL-1, and then
washed again with buffer to remove excess gold beads.
The 3D structure of the clot was viewed by confocal
microscopy on a Leica TCS SP2 and DM IRE2microscope
(Leica Microsystems, Milton Keynes, United Kingdom).
Clot fibers were visualized using a 63x water immersion
lens with a 5-W argon laser and 488 nm laser filter. The
microscope was set up in reflection mode using a 70/30
beam splitter and the images were collected in the format of
Fig. a-d, Serial real time low magnification image512  512 pixels. Optical sectioning was attained by clos-ing the pinhole in front of the detector to 133.7 m and
collecting the reflected light of multiple optical planes in
the z plane. Using the Leica software, three random areas of
the clot were visualized under high magnification to allow
fiber thickness measurement. Optical sections were taken in
1 m z-steps through an area of 20  20  20 m. These
sections were reconstructed to give a single high-magnifi-
cation image, and five fiber diameters were measured in
each image. The calculatedmean of these 15measurements
was then taken as the average fiber thickness (nm).
Lysis was initiated by loading a solution containing 5
g/mL tissue-type plasminogen activator (tPA) (Techno-
clone, Vienna, Austria) and 210 g/mL Glu-Plasminogen
(Enzyme Research, Swansea, United Kingdom) to the
edge of the thrombus in a uniform manner. The slide was
incubated on a flat surface in a moist chamber for 15
minutes and then the edge of the thrombus was scanned,
taking 1 m optical sections in the z-axis through a section
of the thrombus 238  238  20 m in size. These
sections were reconstructed to give an initial image of the
thrombus edge. The visual field was then set and real time
serial scans were taken as the lysis front proceeded across
the visual field digesting the edge of the clot (Fig.). The
velocity of the lysis front (m/minute) was calculated by
measuring the distance the lysis front had moved in a
documented time period between serial scans.
Statistical analysis. To compare normally distributed
data, an independent samples t test was performed. Non-
parametric data were analyzed using the two independent
samples Mann-Whitney U test. Categorical data was cross
tabulated and a 2 test was performed.
Subsequently, all the variables were entered into a back-
ward stepwise linear regressionmodel to determine significant
associations between the traditional reversible cardiovascular
risk factors (ie, smoking, hypertension, hyperlipidemia, and
DM), fibrin clot pore size, fiber thickness by turbidity, and
FXIIIcross-linkingactivity.All statistical analyseswereperformed
with SPSS version 12.0 forWindows (SPSS, Chicago, Ill).
RESULTS
Clinical, anthropometric, biochemical, and hemo-
static characteristics. Table I shows the clinical and an-
thropometric data of the study groups and Table II shows
8  238  20 m) of fibrin clot lysis on LSCM.the biochemical and hemostatic data. The FDR and control
presse
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showed some significant differences for conventional car-
diovascular risk factors, such as smoking and systolic blood
pressure (SBP), where the FDR group had a higher propor-
tion of smokers and a higher SBP. In addition, there were
differences in the biochemical and hemostatic factors as
shown in Table II. There was no statistically significant
difference between study groups for the allele frequency of
the hemostatic polymorphisms (data not shown).
Fibrin clot structure analysis. The results of the fi-
brin clot structure assays are summarized in Table III.
Fibrin clot permeation analysis. When compared
against the control clots, the FDR produced clots which
were less porous, although this difference was not statisti-
Table I. Clinical and anthropometric characteristics of the
Variable
Control
(n  107)
Age (years)† 41 (39-43)
Alcohol (u/week)* 14 (5-25)
Current smoker‡ 21.5%
Ex smoker‡ 15.9%
Never smoker‡ 62.6%
Height (m)* 1.77 (1.73-1.81)
Weight (Kg)† 80 (78-83)
BMI (Kg/m2)† 25.8 (25.1-26.5)
WHR† 0.89 (0.88-0.90)
Pulse (bpm)† 65 (63-68)
SBP (mm Hg)† 128 (125-130)
DBP (mm Hg)† 79 (77-81)
ABPI (left leg)* 1.15 (1.10-1.20)
ABPI (right leg)* 1.15 (1.10-1.20)
FDR, First degree relatives; BMI, body mass index; WHR, waist-hip ratio;
pressure index.
Nonparametric data* is expressed as median (IQR), parametric data† is ex
Alcohol is defined as units consumed per week (u/week), where half a pint
Table II. Biochemical and hemostatic characteristics of th
Variable
Control
(n  107)
Total cholesterol (mmol/L)* 5.2 (4.7-5.9)
LDL cholesterol (mmol/L)† 3.3 (3.2-3.5)
HDL cholesterol (mmol/L)* 1.4 (1.1-1.6)
Triglycerides (mmol/L)* 1.2 (0.9-1.8)
Fasting glucose (mmol/L)* 5.0 (4.7-5.4)
2 hr glucose (mmol/L)* 5.0 (4.5-5.9)
Insulin (m/L)* 6.70 (5.52-10.04
HOMA* 1.35 (1.13-1.80)
Fibrinogen (g/L)* 2.76 (2.47-3.39)
D-dimer (ng/mL)* 43 (32-70)
tPA (ng/mL)† 7.62 (7.01-8.22)
PAI-1 (ng/mL)* 7.9 (3.7-16.7)
FVII activity (%)† 104.2 (99.9-108.5
vWF (iu/mL)* 1.00 (0.78-1.31)
FXIII complex (u/mL)† 1.05 (1.00-1.11)
FXIII B-subunit (u/mL)† 0.98 (0.94-1.03)
FDR, First degree relative; HOMA, homeostasis model assessment of insu
inhibitor-1; vWF, Von Willebrand Factor.
Nonparametric data* is expressed as median (IQR), and parametric data† iscally significant (P  .259).Fibrin polymerization by turbidity analysis and
FXIII cross-linking activity. The FDR produced clots
which were composed of significantly thicker fibers when
measured by turbidity (P .001), and FDR plasma showed
increased FXIII cross-linking activity (P  .001).
LSCM. LSCM confirmed the turbidity findings of
increased fiber thickness in the FDR clots (P  .001). The
fibers had a mean diameter of 315.8 nm in control clots
against 405.1 nm in the FDR group. The lysis front velocity
was significantly slower in the FDR group as compared to
the control group (P .018). The lysis front progressed at
12.66 m/minute in the control clots compared to only
4.83 m/minute in FDR clots.
Linear regression analysis. The positive associations
y groups
FDR
(n  106)
Significance
(P value)
41 (39-43) .843
16 (6-30) .618
50.0%
 .00113.2%
36.8%
1.75 (1.72-1.79) .025
81 (79-84) .635
26.5 (25.6-27.3) .226
0.90 (0.89-0.91) .19
68 (66-71) .084
136 (133-139)  .001
82 (80-84) .063
1.13 (1.08-1.19) .915
1.13 (1.08-1.19) .907
ystolic blood pressure; DBP, diastolic blood pressure; ABPI, ankle brachial
d as mean (95% CI), and categorical data‡ is expressed as the percentage.
r, or 25 mL of hard liquor, or 125 mL of wine, is defined as 1 unit.
dy groups
FDR
(n  106)
Significance
(P value)
5.7 (5.0-6.7) .002
3.7 (3.5-3.9) .02
1.2 (1.0-1.4)  .001
1.9 (1.1-2.5)  .001
5.0 (4.7-5.4) .791
5.2 (4.2-6.6) .233
8.23 (6.60-11.09) .019
1.85 (1.39-2.45)  .001
3.12 (2.67-3.60) .006
52 (30-79) .144
10.36 (9.60-11.13)  .001
10.8 (5.8-21.5) .019
117.0 (111.8-122.2)  .001
1.03 (0.77-1.40) .652
1.18 (1.13-1.24) .001
1.11 (1.06-1.15)  .001
sistance; tPA, tissue plasminogen activator; PAI-1, plasminogen activator
ssed as mean (95% CI).stud
SBP, se stu
)
)
lin reare shown in Table IV. Higher total cholesterol levels were
xpress
pressu
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HDL cholesterol associated with the opposite effect on clot
pore size and also reduced fiber thickness. Increasing LDL
cholesterol and high systolic blood pressure associated pos-
itively with fiber thickness.
DISCUSSION
This study demonstrates that the plasma from healthy
male FDRs of subjects with IC form ex-vivo fibrin clots
which have significantly thicker fibers and increased FXIII
cross-linking activity when compared to a well character-
ized and comparable group of control subjects. The LSCM
images confirmed our findings regarding fiber thickness,
but also showed the lysis front progressed significantly
more slowly in the clots of the FDR. It is important to note
that this LSCM work was in a smaller number of samples.
The assays are equally weighted in importance as each
investigation looks at a different aspect of fibrin structure.
In terms of utility, these assays are not designed for clinical
application currently, however, practically the turbidity as-
say is the easiest and quickest to perform and produced a
highly significant result.
These novel findings support previously published
work from our unit regarding the healthy FDR of subjects
with premature CAD.3 This study reported the healthy
FDR of subjects with CAD form clots that are less perme-
able, with thicker fibers than those formed by controls,3 our
study concurs that the FDR form thicker fibers but the
reduced permeability did not reach statistical significance.
Mills, et al,3 did not continue to assess the impact of these
differences on the fibrinolysis rate, or examine FXIII cross-
linking activity. We found that the FDR of subjects with IC
had an abnormal clot structure which had been seen in
subjects with DM and myocardial infarction.14,21,22
Dynamic LSCM work by Collet, et al,23 investigated
Table III. Fibrin clot structure and function data
Clot parameter Control
Ks  10
9cm2† 15.6 (14.7-16
MA* 0.75 (0.67-0.
FXIII Activity* (%) 105% (87-141
Fiber thickness on LSCM† (nm) 315.8 (307.0-3
Lysis front velocity† (m/min) 12.66 (6.38-18
Nonparametric data* Is expressed as median (IQR) and parametric data † is e
Table IV. Linear regression modelling incorporating cont
variables
Clot parameter Factor
Ks  10
-9cm2 Total cholesterol 
Ks  10
-9cm2 HDL cholesterol
MA LDL cholesterol
MA SBP 0.0
Ks, Average pore size; MA, fiber thickness by turbidity; SBP, systolic bloodthe effect of different fibrin clot characteristics on fibrino-lysis rates. Following real-time fibrinolysis, they reported
that the lysis front moved slower when confronted by a
tight network of thin fibers as compared to a coarse net-
work of thick fibers. Further investigation revealed thicker
fibers took longer to lyse than thinner fibers, leading to the
conclusion that the tight fibrin network arrangement
seemed to be more important than the fibrin diameter in
determining fibrinolysis speed.23 Our study confirms pre-
vious work that this network configuration does detrimen-
tally affect the fibrinolysis rates, but with specific reference
to the clots seen here it raises the question of whether the
risk of a tight network may be further compounded by the
presence of the resistant thick fibers.23
FXIII plays a critical role in fibrin cross-linking and
determines the rigidity and resistance to fibrinolysis of the
clot.24,25 FXIII cross-linking activity was significantly
raised in the FDR group as compared to the control groups
indicating that the FDR clot would be less deformable and
less amenable to fibrinolysis. This increased FXIII cross-
linking combined with the other significantly different clot
parameters may impact upon the clinical outcome for these
subjects and possibly increase the risk of cardiovascular
events. The prevention of permeation of lytic agents due to
the tighter network, in combination with the presence of
more resistant thick fibers and increased FXIII cross-linking,
has demonstrated an increased resistance to fibrinolysis.
This would suggest that, in comparison to the control clots,
in addition to mechanically reducing distal blood flow due
to the clot architecture, the FDR clots would be present for
a longer length of time. Theoretically, these factors could
lead to increased symptomatic cardiovascular events and
end organ damage in the healthy FDR.
It is accepted that claudicants have up to a sixfold
increase in risk of cardiovascular mortality when compared
to a normal population.8 A finding which is not widely
FDR P value
14.6 (13.9-15.3) .259
0.86 (0.75-0.98)  .001
133% (103-155)  .001
) 405.1 (397.6-412.6)  .001
4.83 (2.50-7.17) .018
ed as mean (95% CI).Ks, average pore size;MA, fiber thickness by turbidity.
nd FDR with the clot parameter as the dependent
efficient ()
(95% CI)
Significance
(P value)
Effect
size
(1.32-0.16) .013 4.1
(0.12-4.28) .039 	2.8
(0.6-0.19)  .001 	0.46
(0.0008-0.0034) .002 	0.13
re..6)
93)
)
24.6
.94)rol a
Co
0.74
2.20
0.12
021recognized is the elevated number of cardiovascular events
JOURNAL OF VASCULAR SURGERY
December 20081502 Bhasin et alseen in the FDR of subjects with PVD. Valentine, et al,9
determined the prevalence of early symptomatic CVD in
the FDR of subjects with premature PAD and compared
these subjects to the FDR of healthy subjects. The relative
risk of early CVD in FDR of PAD subjects when compared
to the normal controls was 3.6. Although the FDR of
subjects with PAD have been shown to cluster cardiovas-
cular risk factors and insulin resistance,10 our demonstra-
tion of an altered clot structure and resistance to fibrinolysis
in the FDR clot may contribute to the increased risk of
cardiovascular events.
This study demonstrates a familial association underly-
ing fibrin clot structure, which might be due to a shared
environmental or genetic effect in origin. Fibrin clot struc-
ture is complex with genetic and environmental determi-
nants, and information regarding these interactions is rela-
tively limited.26 This complexity makes the ideal situation
of matching the FDR and control groups for all factors
affecting clot structure virtually impossible within the time
frame for recruitment. We acknowledge that there were
differences in risk factors between the study groups, which
might produce changes in the clot structure, but this work
supports the current published evidence for a familial and
genetic influence on clot structure and the atherothrom-
botic process as a whole.1-3,27 The inheritance of cardio-
vascular risk factors has been demonstrated with heritability
estimates of 21-90% for the conventional risk factors.28-30
In addition, there are high heritability estimates for the
factors involved in the thrombotic process, 44-75% for
hemostatic factors, 40-45% for thrombin generation, and
39-46% for the phenotype of the final fibrin clot.1,2,27
Although the aim of the paper was to compare a healthy
FDR group with a control group, assays were performed on
34 subjects with IC to further understand the mechanism
of familial transmission of an abnormal clot structure.
These subjects have not been included in significant detail
on the basis that these subjects had established clinically
significant disease, and were on cardiovascular medication,
which affect clot structure. In addition, due to the fact that
the FDR group was mainly composed of sons, the IC study
group was significantly older than the other groups. It was,
however, interesting that subjects with IC had significantly
thicker fibers by turbidity and LSCM, significantly higher
levels of FXIII cross-linking, and significantly slower fibri-
nolysis when compared to the control group. The only
significant difference between the IC and FDR group was
that the IC group had thicker fibers on LSCM (Appendix,
online only). The subjects with IC produce an abnormal
clot structure when compared to the control group but
some parameters are similar to those in the FDR group.
This does not clarify whether the abnormal clot structure in
the FDR group is secondary to a severity gradient based on
mutable parameters or a more genetic component.
We used the previously measured parameters10 to de-
tect any significant associations between smoking, hyper-
tension, hyperlipidemia, and diabetes mellitus and the clot
parameters in linear regression analysis. The linear regres-
sion modeling acts solely as an exploratory exercise. Theresults are not conclusive of an underlying mechanism, but
highlight factors which associate with an effect on fibrin
clot structure. We only used the clot variables of permeabil-
ity, fiber thickness by turbidity, and FXIII activity, as anal-
ysis had been performed on all 213 samples rather than a
small selected group as with LSCM.
Increasing total cholesterol was found to associate with
decreased clot permeability, with increasing HDL choles-
terol significantly increasing the porosity of the clot, and
decreasing average fiber diameter. The analysis also showed
that increasing LDL levels associated with thicker fibers.
Certainly these findings support the concept that HDL
cholesterol confers a protective effect and LDL cholesterol
produces a detrimental effect. Jorneskog, et al,15 assessed
the impact of a subcutaneous insulin infusion on the
changes in fibrin structure observed in diabetics. Although
the fibrin gel porosity increased after insulin infusion, this
was independent of improved glycemic control and ap-
peared to be related to improvements in total cholesterol
levels. This indicated that improving total cholesterol may
have a direct beneficial effect on fibrin clot structure.15
Undas, et al,13 demonstrated that treatment with statins
improved the permeability of the clot and Fatah, et al,21
showed that increasing HDL associated with an increase in
the clot permeability. Our analysis supports the above
concepts that HDL cholesterol confers a protective effect
and LDL cholesterol produces a detrimental effect on clot
structure. Although there are correlations between choles-
terol and the clot parameters, this is unlikely to be a primary
cause-effect association as the production of abnormal clot
structure is complex and multi-factorial.
An association was also observed with higher SBP
associating with thicker fibers in the clot. Hypertension is a
well-established risk factor for CVD, with Vogt, et al,31
calculating a 38% increase in risk of PAD for every 10 mm
Hg rise in SBP, but an association between SBP and fibrin
structure has not been characterized. Mills, et al,3 found a
significant association between SBP and clot permeability,
as the SBP increased the clot permeability decreased. Fur-
ther work is necessary to determine how an elevated SBP
produces alterations in clot structure, but some of the
cardiovascular risk conferred by hypertension may be me-
diated by changes in fibrin clot structure.
We have demonstrated that the healthy FDR of sub-
jects with IC form ex-vivo clots that are less porous, have
significantly thicker fibers, increased FXIII cross-linking,
and are more resistant to fibrinolysis as compared to those
of healthy subjects with no family history of CVD. Clearly
these assays for fibrin structure could not be used currently
as clinical diagnostic investigations, but this study may add
to the understanding of the pathophysiology involved in
the development of PAD, suggests a mechanism through
which a positive family history may produce deleterious
effects, and may have implications in the future cardiovas-
cular risk of what is apparently a healthy subgroup of the
population. Previous studies showed the clustering of car-
diovascular risk factors in these FDR10 and we have high-
lighted certain factors such as cholesterol and hypertension
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 6 Bhasin et al 1503that may underpin, through their associations, the produc-
tion of this abnormal clot structure. This study provides a
basis for a clinical and scientific longitudinal follow-up
study to determine whether this abnormal clot structure
persists or worsens, and translates into an increased level of
cardiovascular events. If this is the case, then it raises the
possibility for further studies to assess the impact of lifestyle
counseling and primary prevention in this asymptomatic
group.
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Fibrin clot structure and function data including subjects with intermittent claudication
Clot parameter Control FDR Claudicant
P value
Control
vs FDR
P value
Control vs
Claudicant
P value
FDR vs
Claudicant
Ks  10
-9 cm2† 15.6 (14.7-16.6) 14.6 (13.9-15.3) 13.8 (12.3-15.2) .259 .087 .963
MA* 0.75 (0.67-0.93) 0.86 (0.75-0.98) 0.95 (0.82-1.07) .001 .001 .130
FXIII activity* (%) 105% (87-141) 133% (103-155) 129% (97-156) .001 .042 1.000
Fiber thickness on
LSCM† (nm)
315.8 (307.0-324.6) 405.1 (397.6-412.6) 480.2 (466.9-493.6) .001 .001 .001
Lysis front velocity†
(m/min)
12.66 (6.38-18.94) 4.83 (2.50-7.17) 4.37 (2.89-5.84) .018 .008 1.000
FDR, First degree relative; Ks, Average pore size; MA, fiber thickness by turbidity; LSCM, laser scanning confocal microscopy.
Nonparametric data* is expressed as median (IQR) and parametric data† is expressed as mean (95% CI).
